News | May 29, 2024
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
International Business is expected to register double-digit growth in constant currency terms
Subscribe To Our Newsletter & Stay Updated
